SVF
Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Novel biological therapies for the treatment of diabetic foot ulcers.

Adeghate J., Nurulain S., Tekes K., Fehér E., Kalász H., Adeghate E.

Narrative Review on Diabetic Foot, Chronic Wound, Immune Modulation, published in Expert Opin Biol Ther (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Expert Opin Biol Ther (2017)
Country
England
Reported sample size
—
Source database
PubMed
PMID
28532226
DOI
10.1080/14712598.2017.1333596
Citations
31

Abstract (original English)

Introduction The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Biological ProductsDiabetic FootDiabetic NeuropathiesHumansHypoglycemic AgentsImmunomodulationIntercellular Signaling Peptides and ProteinsStem Cell TransplantationUrokinase-Type Plasminogen ActivatorWound Healing
Ankle & FootSystemic / IVDiabetic FootChronic WoundImmune Modulation
View on PubMedDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “novel biological therapies”View all: author adeghateView all: year 2017

Related research